Adam Turpcu
Adverum Biotechnologies, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam Turpcu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07630649 · Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular DegenerationAdverum Biotechnologies, Inc. · recruiting · Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD · study director
- Ph3NCT07482176 · Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)Adverum Biotechnologies, Inc. · recruiting · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD · study director
- Ph3NCT06856577 · Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationAdverum Biotechnologies, Inc. · active not recruiting · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD · study director
- N/ANCT05607810 · Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)Adverum Biotechnologies, Inc. · active not recruiting · Diabetic Macular Edema, Diabetic Retinopathy · study director
- Ph2NCT05536973 · Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Adverum Biotechnologies, Inc. · active not recruiting · Neovascular Age-related Macular Degeneration · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:37 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.Ophthalmology · 201452 citationsRCR 2.0
- Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.JAMA Ophthalmol · 201618 citationsRCR 1.0
- 17 citationsRCR 1.2